|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RACK1 |
Gene summary for RACK1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RACK1 | Gene ID | 10399 |
| Gene name | receptor for activated C kinase 1 | |
| Gene Alias | GNB2L1 | |
| Cytomap | 5q35.3 | |
| Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | E9KL35 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10399 | RACK1 | GSM4909281 | Human | Breast | IDC | 2.78e-59 | -3.78e-02 | 0.21 |
| 10399 | RACK1 | GSM4909282 | Human | Breast | IDC | 2.17e-64 | 7.13e-02 | -0.0288 |
| 10399 | RACK1 | GSM4909285 | Human | Breast | IDC | 1.23e-25 | 4.45e-01 | 0.21 |
| 10399 | RACK1 | GSM4909286 | Human | Breast | IDC | 5.49e-73 | 1.16e-01 | 0.1081 |
| 10399 | RACK1 | GSM4909287 | Human | Breast | IDC | 1.51e-25 | 6.44e-02 | 0.2057 |
| 10399 | RACK1 | GSM4909289 | Human | Breast | IDC | 1.57e-08 | 2.62e-01 | 0.1064 |
| 10399 | RACK1 | GSM4909290 | Human | Breast | IDC | 1.79e-41 | -6.68e-02 | 0.2096 |
| 10399 | RACK1 | GSM4909291 | Human | Breast | IDC | 8.71e-20 | 4.37e-01 | 0.1753 |
| 10399 | RACK1 | GSM4909293 | Human | Breast | IDC | 3.18e-68 | 2.57e-01 | 0.1581 |
| 10399 | RACK1 | GSM4909294 | Human | Breast | IDC | 3.12e-21 | 1.51e-02 | 0.2022 |
| 10399 | RACK1 | GSM4909295 | Human | Breast | IDC | 4.43e-08 | 2.78e-01 | 0.0898 |
| 10399 | RACK1 | GSM4909296 | Human | Breast | IDC | 4.20e-19 | 5.43e-01 | 0.1524 |
| 10399 | RACK1 | GSM4909297 | Human | Breast | IDC | 1.18e-04 | 2.31e-01 | 0.1517 |
| 10399 | RACK1 | GSM4909298 | Human | Breast | IDC | 1.07e-33 | 4.46e-01 | 0.1551 |
| 10399 | RACK1 | GSM4909299 | Human | Breast | IDC | 3.78e-37 | 3.80e-01 | 0.035 |
| 10399 | RACK1 | GSM4909300 | Human | Breast | IDC | 6.35e-09 | 3.90e-01 | 0.0334 |
| 10399 | RACK1 | GSM4909301 | Human | Breast | IDC | 3.73e-42 | 1.37e-01 | 0.1577 |
| 10399 | RACK1 | GSM4909302 | Human | Breast | IDC | 1.67e-19 | 1.43e-01 | 0.1545 |
| 10399 | RACK1 | GSM4909303 | Human | Breast | IDC | 3.05e-13 | 2.52e-01 | 0.0438 |
| 10399 | RACK1 | GSM4909304 | Human | Breast | IDC | 1.64e-62 | 2.02e-01 | 0.1636 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:20012351 | Colorectum | SER | positive regulation of apoptotic signaling pathway | 36/2897 | 126/18723 | 1.29e-04 | 2.63e-03 | 36 |
| GO:00109501 | Colorectum | SER | positive regulation of endopeptidase activity | 47/2897 | 179/18723 | 1.32e-04 | 2.66e-03 | 47 |
| GO:00342841 | Colorectum | SER | response to monosaccharide | 56/2897 | 225/18723 | 1.52e-04 | 2.98e-03 | 56 |
| GO:00068921 | Colorectum | SER | post-Golgi vesicle-mediated transport | 31/2897 | 104/18723 | 1.59e-04 | 3.08e-03 | 31 |
| GO:19035731 | Colorectum | SER | negative regulation of response to endoplasmic reticulum stress | 17/2897 | 44/18723 | 1.64e-04 | 3.12e-03 | 17 |
| GO:00069861 | Colorectum | SER | response to unfolded protein | 38/2897 | 137/18723 | 1.68e-04 | 3.16e-03 | 38 |
| GO:19058971 | Colorectum | SER | regulation of response to endoplasmic reticulum stress | 26/2897 | 82/18723 | 1.76e-04 | 3.28e-03 | 26 |
| GO:19043771 | Colorectum | SER | positive regulation of protein localization to cell periphery | 23/2897 | 69/18723 | 1.78e-04 | 3.30e-03 | 23 |
| GO:00160551 | Colorectum | SER | Wnt signaling pathway | 97/2897 | 444/18723 | 2.02e-04 | 3.68e-03 | 97 |
| GO:00423261 | Colorectum | SER | negative regulation of phosphorylation | 86/2897 | 385/18723 | 2.10e-04 | 3.78e-03 | 86 |
| GO:01987381 | Colorectum | SER | cell-cell signaling by wnt | 97/2897 | 446/18723 | 2.39e-04 | 4.11e-03 | 97 |
| GO:00301111 | Colorectum | SER | regulation of Wnt signaling pathway | 75/2897 | 328/18723 | 2.47e-04 | 4.20e-03 | 75 |
| GO:20012441 | Colorectum | SER | positive regulation of intrinsic apoptotic signaling pathway | 20/2897 | 58/18723 | 2.76e-04 | 4.59e-03 | 20 |
| GO:00346141 | Colorectum | SER | cellular response to reactive oxygen species | 41/2897 | 155/18723 | 2.89e-04 | 4.74e-03 | 41 |
| GO:00988761 | Colorectum | SER | vesicle-mediated transport to the plasma membrane | 37/2897 | 136/18723 | 3.08e-04 | 5.00e-03 | 37 |
| GO:00336731 | Colorectum | SER | negative regulation of kinase activity | 57/2897 | 237/18723 | 3.48e-04 | 5.46e-03 | 57 |
| GO:00097431 | Colorectum | SER | response to carbohydrate | 60/2897 | 253/18723 | 3.66e-04 | 5.67e-03 | 60 |
| GO:00064691 | Colorectum | SER | negative regulation of protein kinase activity | 52/2897 | 212/18723 | 3.75e-04 | 5.74e-03 | 52 |
| GO:00097491 | Colorectum | SER | response to glucose | 52/2897 | 212/18723 | 3.75e-04 | 5.74e-03 | 52 |
| GO:00064171 | Colorectum | SER | regulation of translation | 100/2897 | 468/18723 | 3.76e-04 | 5.74e-03 | 100 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa051629 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
| hsa0516213 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
| hsa05162 | Lung | IAC | Measles | 27/1053 | 139/8465 | 1.16e-02 | 4.20e-02 | 2.79e-02 | 27 |
| hsa051621 | Lung | IAC | Measles | 27/1053 | 139/8465 | 1.16e-02 | 4.20e-02 | 2.79e-02 | 27 |
| hsa051628 | Oral cavity | OSCC | Measles | 90/3704 | 139/8465 | 4.10e-07 | 2.50e-06 | 1.27e-06 | 90 |
| hsa0516212 | Oral cavity | OSCC | Measles | 90/3704 | 139/8465 | 4.10e-07 | 2.50e-06 | 1.27e-06 | 90 |
| hsa0516241 | Oral cavity | EOLP | Measles | 42/1218 | 139/8465 | 1.11e-06 | 9.96e-06 | 5.87e-06 | 42 |
| hsa051625 | Oral cavity | EOLP | Measles | 42/1218 | 139/8465 | 1.11e-06 | 9.96e-06 | 5.87e-06 | 42 |
| hsa051626 | Oral cavity | NEOLP | Measles | 35/1112 | 139/8465 | 8.30e-05 | 6.14e-04 | 3.86e-04 | 35 |
| hsa051627 | Oral cavity | NEOLP | Measles | 35/1112 | 139/8465 | 8.30e-05 | 6.14e-04 | 3.86e-04 | 35 |
| hsa051624 | Prostate | BPH | Measles | 42/1718 | 139/8465 | 3.35e-03 | 1.23e-02 | 7.61e-03 | 42 |
| hsa0516211 | Prostate | BPH | Measles | 42/1718 | 139/8465 | 3.35e-03 | 1.23e-02 | 7.61e-03 | 42 |
| hsa051622 | Prostate | Tumor | Measles | 44/1791 | 139/8465 | 2.33e-03 | 8.85e-03 | 5.49e-03 | 44 |
| hsa051623 | Prostate | Tumor | Measles | 44/1791 | 139/8465 | 2.33e-03 | 8.85e-03 | 5.49e-03 | 44 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RACK1 | SNV | Missense_Mutation | c.260N>G | p.Leu87Arg | p.L87R | P63244 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0SW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | PD | |
| RACK1 | SNV | Missense_Mutation | novel | c.923N>C | p.Arg308Pro | p.R308P | P63244 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
| RACK1 | SNV | Missense_Mutation | c.357N>T | p.Gln119His | p.Q119H | P63244 | protein_coding | deleterious(0.01) | possibly_damaging(0.905) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| RACK1 | SNV | Missense_Mutation | rs745953408 | c.53N>G | p.Val18Gly | p.V18G | P63244 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A1F2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| RACK1 | SNV | Missense_Mutation | novel | c.32N>C | p.Leu11Pro | p.L11P | P63244 | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD |
| RACK1 | SNV | Missense_Mutation | rs745953408 | c.53N>G | p.Val18Gly | p.V18G | P63244 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EW-A1IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD |
| RACK1 | insertion | Frame_Shift_Ins | novel | c.819_820insCTTAATTCAAAACTAATTTATTCCTCAGGTCAAAAGTTTTGGGGTGG | p.Val274LeufsTer55 | p.V274Lfs*55 | P63244 | protein_coding | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| RACK1 | insertion | Nonsense_Mutation | novel | c.799_800insGAGCCTTATCACCAGCTGTTTCTTCCTCAAGGAATACATAACCAC | p.Val267delinsGlyAlaLeuSerProAlaValSerSerSerArgAsnThrTerProLeu | p.V267delinsGALSPAVSSSRNT*PL | P63244 | protein_coding | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| RACK1 | deletion | Frame_Shift_Del | novel | c.334delN | p.Ala112ProfsTer73 | p.A112Pfs*73 | P63244 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| RACK1 | SNV | Missense_Mutation | novel | c.262N>T | p.Arg88Cys | p.R88C | P63244 | protein_coding | deleterious(0.02) | benign(0.071) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |